WallStreetZenWallStreetZen

NASDAQ: NTLA
Intellia Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for NTLA

Based on 15 analysts offering 12 month price targets for Intellia Therapeutics Inc

Min Forecast
$10.00+16.96%
Avg Forecast
$35.33+313.25%
Max Forecast
$90.00+952.63%

Should I buy or sell NTLA stock?

Based on 15 analysts offering ratings for Intellia Therapeutics Inc.

Buy
Strong Buy
6 analysts 40%
Buy
4 analysts 26.67%
Hold
5 analysts 33.33%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although NTLA's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates NTLA as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their NTLA stock forecasts and price targets.

NTLA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-05-12
lockedlocked$00.00+00.00%2025-05-09
lockedlocked$00.00+00.00%2025-05-09
lockedlocked$00.00+00.00%2025-04-21
lockedlocked$00.00+00.00%2025-03-05
Truist Securities
Top 3%
98
Strong BuyMaintains$50.00+484.80%2025-03-04
Barclays
Bottom 4%
4
Strong BuyMaintains$26.00+204.09%2025-02-28
Wells Fargo
Bottom 14%
14
Strong BuyMaintains$50.00+484.80%2025-02-28
JP Morgan
Bottom 5%
5
HoldDowngrades$13.00+52.05%2025-02-28
Morgan Stanley
Top 10%
91
HoldDowngrades$11.00+28.65%2025-01-27

1 of 2

Forecast return on equity

Is NTLA forecast to generate an efficient return?

Company
67.78%
Industry
139.85%
Market
90.26%
NTLA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is NTLA forecast to generate an efficient return on assets?

Company
53.6%
Industry
37.22%
NTLA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NTLA earnings per share forecast

What is NTLA's earnings per share in the next 3 years based on estimates from 13 analysts?

Avg 1 year Forecast
-$4.62
Avg 2 year Forecast
-$4.62
Avg 3 year Forecast
-$0.78

NTLA revenue forecast

What is NTLA's revenue in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
$56.0M+22.87%
Avg 2 year Forecast
$42.6M-6.54%
Avg 3 year Forecast
$581.2M+1,175.5%
NTLA's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

NTLA revenue growth forecast

How is NTLA forecast to perform vs Biotechnology companies and vs the US market?

Company
117.41%
Industry
57.37%
Market
9.64%
NTLA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
NTLA's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

NTLA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
NTLA$8.55$35.33+313.25%Buy
SYRE$14.93$55.00+268.39%Buy
PHVS$16.81$41.50+146.88%Strong Buy
ARDX$3.53$10.07+185.30%Strong Buy
ELVN$19.01$40.33+112.17%Strong Buy
View Top Biotech Stocks

Intellia Therapeutics Stock Forecast FAQ

Is Intellia Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 15 Wall Street analysts covering (NASDAQ: NTLA) stock is to Buy NTLA stock.

Out of 15 analysts, 6 (40%) are recommending NTLA as a Strong Buy, 4 (26.67%) are recommending NTLA as a Buy, 5 (33.33%) are recommending NTLA as a Hold, 0 (0%) are recommending NTLA as a Sell, and 0 (0%) are recommending NTLA as a Strong Sell.

If you're new to stock investing, here's how to buy Intellia Therapeutics stock.

What is NTLA's earnings growth forecast for 2025-2027?

(NASDAQ: NTLA) Intellia Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.76%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.53%.

Intellia Therapeutics's earnings in 2025 is -$525,914,000.On average, 13 Wall Street analysts forecast NTLA's earnings for 2025 to be -$479,031,764, with the lowest NTLA earnings forecast at -$591,461,180, and the highest NTLA earnings forecast at -$330,431,027. On average, 12 Wall Street analysts forecast NTLA's earnings for 2026 to be -$478,897,105, with the lowest NTLA earnings forecast at -$608,034,523, and the highest NTLA earnings forecast at -$299,356,009.

In 2027, NTLA is forecast to generate -$80,795,047 in earnings, with the lowest earnings forecast at -$536,561,981 and the highest earnings forecast at $2,328,554,697.

What is NTLA's revenue growth forecast for 2025-2027?

(NASDAQ: NTLA) Intellia Therapeutics's forecast annual revenue growth rate of 117.41% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 57.37%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.64%.

Intellia Therapeutics's revenue in 2025 is $45,569,000.On average, 9 Wall Street analysts forecast NTLA's revenue for 2025 to be $5,799,530,647, with the lowest NTLA revenue forecast at $932,250,546, and the highest NTLA revenue forecast at $21,752,512,740. On average, 9 Wall Street analysts forecast NTLA's revenue for 2026 to be $4,411,306,000, with the lowest NTLA revenue forecast at $932,250,546, and the highest NTLA revenue forecast at $10,358,339,400.

In 2027, NTLA is forecast to generate $60,206,190,428 in revenue, with the lowest revenue forecast at $378,079,388 and the highest revenue forecast at $392,188,482,197.

What is NTLA's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: NTLA) forecast ROA is 53.6%, which is higher than the forecast US Biotechnology industry average of 37.22%.

What is NTLA's Price Target?

According to 15 Wall Street analysts that have issued a 1 year NTLA price target, the average NTLA price target is $35.33, with the highest NTLA stock price forecast at $90.00 and the lowest NTLA stock price forecast at $10.00.

On average, Wall Street analysts predict that Intellia Therapeutics's share price could reach $35.33 by May 12, 2026. The average Intellia Therapeutics stock price prediction forecasts a potential upside of 313.25% from the current NTLA share price of $8.55.

What is NTLA's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: NTLA) Intellia Therapeutics's current Earnings Per Share (EPS) is -$5.22. On average, analysts forecast that NTLA's EPS will be -$4.62 for 2025, with the lowest EPS forecast at -$5.71, and the highest EPS forecast at -$3.19. On average, analysts forecast that NTLA's EPS will be -$4.62 for 2026, with the lowest EPS forecast at -$5.87, and the highest EPS forecast at -$2.89. In 2027, NTLA's EPS is forecast to hit -$0.78 (min: -$5.18, max: $22.48).

What is NTLA's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: NTLA) forecast ROE is 67.78%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.